共 31 条
[1]
BACHUR NR, 1977, CLIN PHARMACOL THER, V21, P70
[2]
Baldessarini R. J., 1980, PHARMACOL BASIS THER, P391
[3]
CHABNER BA, 1986, J CLIN ONCOL, V4, P625
[4]
CURT GA, 1984, CANCER TREAT REP, V68, P87
[6]
TUMOR HETEROGENEITY AND DRUG-RESISTANCE
[J].
JOURNAL OF CLINICAL ONCOLOGY,
1986, 4 (02)
:244-257
[7]
CORRELATION BETWEEN POTENCY OF CALMODULIN INHIBITORS AND EFFECTS ON CELLULAR-LEVELS AND CYTO-TOXIC ACTIVITY OF DOXORUBICIN (ADRIAMYCIN) IN RESISTANT P388 MOUSE LEUKEMIA-CELLS
[J].
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY,
1984, 20 (06)
:799-806
[8]
GANAPATHI R, 1983, CANCER RES, V43, P3696
[9]
DIFFERENTIAL EFFECT OF THE CALMODULIN INHIBITOR TRIFLUOPERAZINE IN MODULATING CELLULAR ACCUMULATION, RETENTION AND CYTO-TOXICITY OF DOXORUBICIN IN PROGRESSIVELY DOXORUBICIN-RESISTANT L1210 MOUSE LEUKEMIA-CELLS - LACK OF CORRELATION BETWEEN CELLULAR DOXORUBICIN LEVELS AND EXPRESSION OF RESISTANCE
[J].
BIOCHEMICAL PHARMACOLOGY,
1988, 37 (02)
:185-193
[10]
GANAPATHI R, 1984, CANCER RES, V44, P5056